中国国际金融股份有限公司 关于成都先导药物开发股份有限公司 股东向特定机构投资者询价转让股份 相关资格的核查意见 中国国际金融股份有限公司（以下简称"中金公司"）受成都先导药物开发股份有 限公司（以下简称"上市公司"、"公司"或"成都先导"）股东钧天创业投资有限公 司（以下简称"钧天创投"）及拉萨经济技术开发区华博医疗器械有限公司（以下简称 "华博医疗"）（以下合称"出让方"）委托，组织实施本次成都先导股东向特定机构 投资者询价转让（以下简称"本次询价转让"）。 根据《关于在上海证券交易所设立科创板并试点注册制的实施意见》《科创板上市 公司持续监管办法（试行）》《上海证券交易所科创板股票上市规则》《上海证券交易 所科创板上市公司股东以向特定机构投资者询价转让和配售方式减持股份实施细则》 （以下简称"《实施细则》"）等相关规定，中金公司对参与本次询价出让方的相关资 本次询价转让的委托情况、出让方相关资格的核查情况及核查意见如下： 一、本次询价转让概述 中金公司已收到出让方关于本次询价转让的委托，委托中金公司组织实施本次询价 转让。 二、关于参与本次询价转让股东相关资格的核查情况 （一）核查过程 根据相关法规要求 ...

Financial Performance - In 2023, the company achieved revenue of CNY 371 million, a year-on-year increase of 12.64% [15] - The net profit attributable to shareholders was CNY 40.72 million, up 61.16% year-on-year [15] - The overall gross profit margin for core business was 49.28%, an increase of 1.61 percentage points year-on-year [15] - Operating cash flow net amount reached CNY 125 million, a year-on-year growth of 137.42% [15] Revenue Breakdown by Platform - DEL platform revenue was CNY 183.58 million, a year-on-year increase of 25.45% [15] - FBDD/SBDD platform revenue was CNY 91.78 million, a decrease of 11.13% year-on-year [15] - STO platform revenue was CNY 34.38 million, a decrease of 10.62% year-on-year, but service revenue grew by 60.16% [16] - TPD platform revenue was CNY 18.52 million, an increase of 111.85% year-on-year [16] Research and Development Focus - The company has been actively integrating AI in drug discovery, particularly through the DEL+AI platform [9][14] - The DEL technology has been developed and applied for over 10 years, making the company a leader in the field [6] - The average success rate for screening projects in the past three years is nearly 80%, higher than the industry average for HTS [7][12] Strategic Initiatives - The company is focusing on expanding its DEL technology applications to meet specific client needs, such as DEL For Protein Degradation and DEL For GPCRs [8] - The integration of high-throughput synthesis and compound testing platforms aims to accelerate the drug discovery process [9][14] - The company is enhancing collaboration between its UK subsidiary and domestic teams to improve project success rates and efficiency [10][11] Market Position and Competitiveness - Chengdu XianDao is recognized as one of the leading companies in DEL technology, with numerous collaborations with major pharmaceutical companies [6][7] - The company has published over 30 original scientific papers in the DEL field, contributing to technological innovation [6] - The company has accumulated experience in screening hundreds of targets across more than 53 target types [12][13]

Financial Performance - 2023 revenue: 3.71 billion RMB, a 12.64% year-on-year increase [15] - 2023 net profit: 407.185 million RMB, a 61.16% year-on-year increase [15] - 2023 gross margin: 49.28%, up 1.61 percentage points [15] - 2023 operating cash flow: 1.25 billion RMB, a 137.42% year-on-year increase [15] - Q1 2024 revenue: 1.07 billion RMB, a 54.35% year-on-year increase [16] - Q1 2024 net profit: 139.4 million RMB, turning from negative to positive [16] Platform Performance - DEL platform revenue in 2023: 1.835815 billion RMB, a 25.45% year-on-year increase [15] - FBDD/SBDD platform revenue in 2023: 917.783 million RMB, an 11.13% year-on-year decrease [15] - STO platform revenue in 2023: 343.778 million RMB, a 10.62% year-on-year decrease (excluding self-developed pipeline transfers, service revenue increased by 60.16%) [16] - TPD platform revenue in 2023: 185.25 million RMB, a 111.85% year-on-year increase [16] DEL Technology - DEL screening success rate: nearly 80% over the past three years, higher than the industry average for HTS [7][12] - Number of target types screened: over 53 categories, including protein-protein interactions, transcription factors, and more [7][12] - Number of compound IP transfers: 86 projects (>800 compound entities) completed by the end of 2023 [13] - Published over 30 original scientific papers in the DEL field [6] - Awarded "CAS REGISTRY ® INNOVATOR" certificate twice, with 91 novel compounds receiving unique CAS Registry Numbers [7] AI Integration - DEL+AI platform leverages DEL's massive data output and AI's processing capabilities to predict compound activity and druggability [14] - Over 53 target types and hundreds of DEL screening projects provide unique, high-quality experimental data for AI training [14] - AI integration aims to accelerate lead compound discovery and optimization, particularly for challenging targets [14] International Operations - UK subsidiary Vernalis (R&D) Limited focuses on FBDD/SBDD technology, with a gross margin of around 20% [10] - Vernalis' FTE pricing and costs are higher than domestic operations, aligning with European industry averages [10] - Efforts to enhance collaboration between domestic and UK teams to improve project success rates and milestone revenues [10] Market Trends and Competitiveness - Global DEL technology adoption is accelerating, with Chengdu Lead being a pioneer in China and a leader in the field [6] - Collaborations with major international pharmaceutical companies such as Pfizer, Johnson & Johnson, and Merck [6] - Focus on emerging mechanisms like protein degradation and GPCRs through specialized DEL For series [8] Risk Management - Foreign currency deposits primarily in USD, GBP, and EUR, with measures to mitigate exchange rate fluctuations [11]

中国国际金融股份有限公司 关于成都先导药物开发股份有限公司 2023 年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规则》 《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有关法律、法规的 规定，中国国际金融股份有限公司（以下简称"保荐机构"）作为成都先导药物开发股份 有限公司（以下简称"成都先导"、"公司"）持续督导工作的保荐机构，负责成都先导上 市后的持续督导工作，并出具本持续督导跟踪报告。 一、持续督导工作情况 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度，并针对具 | 保荐机构已建立并有效执行了持续 | | | 体的持续督导工作制定相应的工作计划 | 督导制度，并制定了相应的工作计 | | | | 划 | | 2 | | | | | 根据中国证监会相关规定，在持续督导工作开始前， 与上市公司或相关当事人签署持续督导协议，明确 | 保荐机构已与成都先导签订《保荐 协议》，该协议明确了双方在持续督 | | | 双方在持续督导期间的权利义务，并报上海证券交 | 导 ...

关于成都先导药物开发股份有限公司 首次公开发行股票并在科创板上市的保荐总结报告书 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意成都先导药物开 发股份有限公司首次公开发行股票注册的批复》（证监许可[2020]429 号）核准并经上海 证券交易所同意，成都先导药物开发股份有限公司（以下简称"成都先导"或"公司"） 获准公开发行 40,680,000 股人民币普通股（A 股）股票，募集资金总额人民币 834,753,600.00 元。 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为公司首次公 开发行股票并在科创板上市的保荐机构，根据《上海证券交易所科创板股票上市规则》 的相关规定，中金公司的持续督导期间为 2020 年 4 月 16 日至 2023 年 12 月 31 日。截至 2023 年 12 月 31 日，前述持续督导期限已届满。 截至 2023 年 12 月 31 日，公司首次公开发行的募集资金尚未使用完毕，中金公司将 对其募集资金使用情况继续履行持续督导义务。 中金公司根据《证券发行上市保荐业务管理办法》《上海证券交易所上市公司自律 监管指引第 11 号——持续督导》《 ...

成都先导药物开发股份有限公司 关于公司监事辞职的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688222 证券简称：成都先导 公告编号：2024-017 成都先导药物开发股份有限公司（以下简称"公司"）监事会于近日收到公 司监事柳丹先生的辞职申请，柳丹先生表示因个人工作调整原因申请辞去公司监 事会监事职务。辞职后柳丹先生不再担任公司任何职务。柳丹先生辞职后将导致 公司监事会人数低于法定人数，为保障公司监事会补选监事的顺利过渡，在补选 出的监事就任前，柳丹先生将依照法律、行政法规和《公司章程》的规定，继续 履行监事职责。截至本公告披露日，柳丹先生未持有公司股份，不存在应当履行 而未履行的承诺事项。公司将按照法定程序尽快完成监事的补选工作。 柳丹先生在担任公司监事期间恪尽职守、勤勉尽责，为公司的规范运作和健 康发展发挥了积极作用。在此，公司及公司监事会对柳丹先生在任职期间为公司 做出的贡献表示衷心感谢。 特此公告。 成都先导药物开发股份有限公司监事会 2024 年 5 月 7 日 1 ...

证券代码：688222 证券简称：成都先导 公告编号：2024-016 成都先导药物开发股份有限公司 会议召开时间：2024 年 5 月 16 日(星期四) 下午 15:00-16:00 会议召开地点： 上海证券 交易所上证路演中心（ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年度 及 2024 年第一季度的经营成果及财务指标的具体情况与投资者进行 互动交流和沟通，在信息披露允许的范围内就投资者普遍关注的问题 进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2024 年 5 月 16 日 下午 15:00-16:00 （二）会议召开地点：上证路演中心 关于召开 2023 年度暨 2024 年第一季度业绩说明会 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2024 年 5 月 9 日(星期四) 至 5 月 15 日(星期三)16:00 ...

Financial Performance - The company's revenue for 2023 was 371 million CNY, representing a year-on-year growth of 12.64%[5][6] - The net profit attributable to shareholders was 4,071.85 CNY, with a non-recurring net profit of 345.19 CNY, showing a year-on-year increase of 61.16%[7][8] - Operating cash flow net amount was 125 million CNY, with R&D investment totaling 79.61 million CNY, accounting for 21.44% of revenue[10] - The overall gross margin for the main business was 49.28%, reflecting a year-on-year increase of 137.42%[10][11] - In Q1 2024, the company reported revenue of 107 million CNY, a year-on-year increase of 54.35%[25][24] Research and Development - The R&D investment in Q1 2024 was 12.10% of revenue, amounting to approximately 12.99 million CNY[26] - The company has completed over 50 novel E3 ubiquitin ligases, available for direct customer orders, enhancing its service offerings[41] - The DEL library now contains over 12 trillion molecules, with more than 6,000 scaffold types and nearly 40,000 synthetic building blocks, showcasing its extensive capabilities[37] - The company has multiple drug development projects in various stages, with three projects in Phase I clinical trials: HG030, HG381, and HG146, with HG146's Phase I clinical trial for multiple myeloma officially ending in July 2023[57] - The company has a total of 374 R&D personnel, with 97% holding a bachelor's degree or higher[51] - The company has filed for 296 invention patents and 119 software copyrights in 2023, with 43 patents granted[54] - The company is currently constructing a global drug R&D and production base in Chengdu[49] - Two projects are in the IND application preparation stage: HG153 and HG248[57] - The company has developed an internationally leading DNA-encoded compound library technology platform, focusing on small molecule and nucleic acid drug discovery and optimization[64] - The company has two projects in the preclinical candidate compound (PCC) screening stage: HGP0508 and HGP1069[57] Collaborations and Partnerships - The company has established deep collaborations with several global biopharmaceutical companies and research institutions in 2023, including ARase Therapeutics and Pierre Fabre Laboratories[47] Shareholder Returns - The company distributed a cash dividend of 0.5 yuan per 10 shares in 2023, totaling 19.97 million yuan, and has returned over 110 million yuan to investors through dividends and buybacks since its listing[66] Awards and Recognition - The company has received the "ESG Golden Bull Award" for its technological leadership in the first National Cup by China Securities Journal and Guoxin Consulting[67] Business Development - The DEL platform revenue increased by 49.33% during the reporting period, highlighting its significance in the company's business development[28] - The FBDD/SBDD platform saw a revenue increase of 78.83% due to project milestone income and favorable exchange rate changes[28]

一、本次现场检查的基本情况 （一）保荐机构：中国国际金融股份有限公司 （二）保荐代表人：张韦弦、潘闽松 中国国际金融股份有限公司 关于成都先导药物开发股份有限公司 2023 年度持续督导现场检查报告 上海证券交易所： 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为 成都先导药物开发股份有限公司（以下简称"成都先导"或"公司"）的保荐机 构，负责对成都先导的持续督导工作。根据《证券发行上市保荐业务管理办法》 《上海证券交易所上市公司自律监管指引第11号——持续督导》等有关法律、法 规的规定，中金公司作为正在履行成都先导持续督导工作的保荐机构，对公司 2023年1月1日至2023年12月31日期间（以下简称"本持续督导期间"）的规范运 作情况进行了现场检查，现就现场检查的有关情况报告如下： （三）现场检查时间：2024年4月22日 （四）现场检查人员：潘闽松、崔诗晨 （五）现场检查内容：公司治理和内部控制、信息披露、独立性、与关联方 的资金往来、募集资金使用情况、关联交易、对外担保、重大对外投资、公司经 营状况以及承诺履行情况等。 （六）现场检查手段：与公司相关部门负责人员进行沟通；查阅公司公 ...

证券代码：688222 证券简称：成都先导 成都先导药物开发股份有限公司 投资者关系活动记录表 （2024年4月25日） □特定对象调研 R分析师会议 □媒体采访 £业绩说明会 投资者关系活动 □新闻发布会 £路演活动 类别 □现场参观 R其他 （电话会议） 参与单位名称 2024年4月25日 15:30-17:00（分析师电话会议）: 中金医药、中泰医药、民生医药、财通医药、国信医药、 国盛医药、国金医药、兴业医药、华西医药、海通医药、 ...